AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26437922 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based weight management intervention (24 weeks)
Number of subjects: 61
Study 25501074 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture using a pragmatic placebo needle (no skin penetration)
Number of subjects: 60
Study 25501074 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture using a real needle (15 mm skin penetration)
Number of subjects: 60
Study 22651946 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based parenteral hydration therapy
Number of subjects: 161
Study 20175126 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted ileocolic resection
Number of subjects: 60
Study 20175126 — intervention group
Group type: COMPARATOR
Intervention: Open ileocolic resection
Number of subjects: 60
Study 18822977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint-injection group (2 mg Morphine into bilateral Neiguan (PC 6))
Number of subjects: 90
Study 18822977 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection group (5 mg Morphine)
Number of subjects: 90
Study 18822977 — intervention group
Group type: COMPARATOR
Intervention: Hypodermic injection group (5 mg Morphine)
Number of subjects: 90
Study 16884978 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (40 mg)
Number of subjects: 46
Study 16884978 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1,000 mug)
Number of subjects: 46
Study 14695923 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg t.i.d.
Number of subjects: 550
Study 14695923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study 10787771 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite-plus-family condition
Number of subjects: 1359
Study 10787771 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite-only condition
Number of subjects: 1359
Study 10787771 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control
Number of subjects: 1359
Study 8792791 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally coordinated quality assurance intervention
Number of subjects: 16
Study 8792791 — intervention group
Group type: COMPARATOR
Intervention: Internal quality assurance
Number of subjects: 16
Study 1377295 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 96
Study 1377295 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 6337131 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 44
Study 6337131 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 44
Study 30737332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 816
Study 30737332 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 816
Study 30737332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 816
Study 30737332 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 816
Study 27643913 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of scripted, classroom-based, book-based intervention targeting code- and meaning-related emergent literacy skills.
Number of subjects: 137
Study 27643913 — intervention group
Group type: COMPARATOR
Intervention: Business as usual control group (2 classes).
Number of subjects: 137
Study 27195435 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ramosetron
Number of subjects: 1102
Study 27195435 — intervention group
Group type: COMPARATOR
Intervention: 4 mg ondansetron
Number of subjects: 1102
Study 25048500 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 200
Study 25048500 — intervention group
Group type: COMPARATOR
Intervention: Loxoprofen
Number of subjects: 200
Study 25048500 — intervention group
Group type: COMPARATOR
Intervention: Tramadol/acetaminophen
Number of subjects: 200
Study 22760642 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with 10 mg Fe/L as ferrous sulfate
Number of subjects: 28
Study 22760642 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with 10 mg Fe/L and 5 mg Zn/L as Zn sulfate
Number of subjects: 28
Study 22760642 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with 10 mg Fe/L and 10 mg Zn/L as Zn sulfate
Number of subjects: 28
Study 22760642 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with 10 mg Fe/L and 20 mg Zn/L as Zn sulfate
Number of subjects: 28
Study 22760642 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with 10 mg Fe/L and ascorbic acid (70 mg/L)
Number of subjects: 28
Study 22760642 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with 10 mg Fe/L and 5 mg Zn/L as Zn sulfate and ascorbic acid (70 mg/L)
Number of subjects: 28
Study 22760642 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with 10 mg Fe/L and 10 mg Zn/L as Zn sulfate and ascorbic acid (70 mg/L)
Number of subjects: 28
Study 22760642 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with 10 mg Fe/L and 20 mg Zn/L as Zn sulfate and ascorbic acid (70 mg/L)
Number of subjects: 28
Study 21344836 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth with ferrule (>2 mm height) - Group A (45 teeth)
Number of subjects: 87
Study 21344836 — intervention group
Group type: COMPARATOR
Intervention: Teeth without ferrule (<2 mm height) - Group B (42 teeth)
Number of subjects: 87
Study 21344836 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall restorations
Number of subjects: 87
Study 21344836 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisors
Number of subjects: 87
Study 17661199 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous opioid withdrawal (OW)
Number of subjects: 6
Study 17661199 — intervention group
Group type: COMPARATOR
Intervention: No spontaneous opioid withdrawal (absence of OW)
Number of subjects: 6
Study 15644005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 51
Study 15644005 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Tube (LT)
Number of subjects: 51
Study 12133500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifendate (higher doses: 30-45 mg/d for ages <= 12, 45-67.5 mg/d for ages > 12) for up to 12 months
Number of subjects: 119
Study 12133500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifendate (higher doses)
Number of subjects: 119
Study 12133500 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 119
Study 10416048 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleate-rich diet (MUFA)
Number of subjects: 22
Study 10416048 — intervention group
Group type: COMPARATOR
Intervention: Linoleate-rich diet (PUFA)
Number of subjects: 22
Study 7575719 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (MAb) CAMPATH‐1H treatment
Number of subjects: 10
Study 1710655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (40 mg/m2 daily for 5 days)
Number of subjects: 159
Study 1710655 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cisplatin (20 mg/m2 daily for 5 days)
Number of subjects: 159
Study 1710655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin
Number of subjects: 159
Study 1710655 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cisplatin
Number of subjects: 159
Study 7233157 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium water (107 mg Na/L)
Number of subjects: 0
Study 7233157 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium water (from low sodium community with no sodium added)
Number of subjects: 0
Study 7233157 — intervention group
Group type: COMPARATOR
Intervention: Low sodium water (from comparison community with sodium added to high sodium level)
Number of subjects: 0
Study 7233157 — intervention group
Group type: COMPARATOR
Intervention: High sodium water (from high sodium community)
Number of subjects: 0
Study 30293198 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (70 µg [2800 IU] daily for 3 months)
Number of subjects: 81
Study 30293198 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 81
Study 30293198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 29958037 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM (psychotherapeutic intervention)
Number of subjects: 305
Study 29958037 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 305
Study 27798013 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 (13-valent pneumococcal conjugate vaccine)
Number of subjects: 1040
Study 27798013 — intervention group
Group type: COMPARATOR
Intervention: PCV7 (7-valent pneumococcal conjugate vaccine)
Number of subjects: 1040
Study 25132608 — intervention group
Group type: EXPERIMENTAL
Intervention: Four nights of REM sleep deprivation (RD)
Number of subjects: 31
Study 25132608 — intervention group
Group type: COMPARATOR
Intervention: Normal uninterrupted sleep (Control)
Number of subjects: 31
Study 25132608 — intervention group
Group type: EXPERIMENTAL
Intervention: Two nights of total sleep deprivation (TD)
Number of subjects: 31
Study 22156917 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine diacetate 10% weight per volume (w/v) dental coating (CHX)
Number of subjects: 983
Study 22156917 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 983
Study 19129748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (2.5-100 mg daily for 14 days)
Number of subjects: 0
Study 19129748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (20-50 mg)
Number of subjects: 0
Study 19129748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 17849143 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-guided training (n = 9)
Number of subjects: 26
Study 17849143 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TRA) (n = 8)
Number of subjects: 26
Study 17849143 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 26
Study 15512856 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg PAS
Number of subjects: 80
Study 15512856 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg PAS
Number of subjects: 80
Study 15512856 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg PAS
Number of subjects: 80
Study 15512856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 11158017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (estradiol valerate at 2 mg/day for 11 days and cyproterone acetate at 1 mg/day for 10 days; group C)
Number of subjects: 60
Study 11158017 — intervention group
Group type: COMPARATOR
Intervention: Estradiol alone (patches with E(2) release of 50 microg/24 h; group B)
Number of subjects: 60
Study 11158017 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 60
Study 9747678 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol swabs (cleaned group)
Number of subjects: 66
Study 9747678 — intervention group
Group type: COMPARATOR
Intervention: Control (not cleaned)
Number of subjects: 66
Study 7839099 — intervention group
Group type: EXPERIMENTAL
Intervention: Nested primer polymerase chain reaction (PCR) for detection of Mycobacterium paratuberculosis DNA
Number of subjects: 24
Study 2852540 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre yoghurt (150 ml containing lactitol, guar gum, and wheat bran) twice daily for 2 weeks
Number of subjects: 33
Study 2852540 — intervention group
Group type: COMPARATOR
Intervention: Control yoghurt (150 ml without lactitol, guar gum, or wheat bran) twice daily for 2 weeks
Number of subjects: 33
Study 31359842 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery (MI)
Number of subjects: 48
Study 31359842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile feedback (TF)
Number of subjects: 48
Study 31359842 — intervention group
Group type: COMPARATOR
Intervention: Common verbal explanation (MCTE-control group)
Number of subjects: 48
Study 29980042 — intervention group
Group type: COMPARATOR
Intervention: 0 ppb (filtered air)
Number of subjects: 87
Study 29980042 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 ppb ozone
Number of subjects: 87
Study 29980042 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 ppb ozone
Number of subjects: 87
Study 28211169 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-1040 (0.1 mg to 40 mg, administered as a 0.5-h intravenous infusion or as a 24-h continuous infusion)
Number of subjects: 103
Study 28211169 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-1040
Number of subjects: 103
Study 28211169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 26742971 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U BoNTA
Number of subjects: 80
Study 26742971 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U BoNTA
Number of subjects: 80
Study 23472879 — intervention group
Group type: EXPERIMENTAL
Intervention: NO₂⁻ infusion (0.31 to 7.8 μmol·min⁻¹)
Number of subjects: 41
Study 23472879 — intervention group
Group type: EXPERIMENTAL
Intervention: NO₂⁻ infusion
Number of subjects: 41
Study 21676059 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial ECG and early cardiac marker elevations
Number of subjects: 2000
Study 21676059 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive initial troponin
Number of subjects: 2000
Study 21676059 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of coronary artery disease (CAD)
Number of subjects: 2000
Study 21676059 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal ECG on arrival
Number of subjects: 2000
Study 21676059 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated lipids
Number of subjects: 2000
Study 21676059 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior AMI
Number of subjects: 2000
Study 21676059 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model including family history of CAD, abnormal initial ECG, and positive initial troponin
Number of subjects: 2000
Study 19085579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 micro g/day
Number of subjects: 1568
Study 19085579 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 640 micro g/day
Number of subjects: 1568
Study 15367196 — intervention group
Group type: COMPARATOR
Intervention: Professional polishing with a rubber cup/point using dentifrice as abrasive paste for 10 min
Number of subjects: 90
Study 15367196 — intervention group
Group type: COMPARATOR
Intervention: Professional brushing with an electric toothbrush (ETB) for 2 min
Number of subjects: 90
Study 15367196 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional brushing with an electric toothbrush (ETB) for 10 min
Number of subjects: 90
Study 10196018 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of chronic nephritis
Number of subjects: 94
Study 10196018 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility to the common cold
Number of subjects: 94
Study 10196018 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for salty foods
Number of subjects: 94
Study 10196018 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent consumption of raw eggs
Number of subjects: 94
Study 10196018 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of carbohydrates (including rice)
Number of subjects: 94
Study 10196018 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 94
Study 10196018 — intervention group
Group type: COMPARATOR
Intervention: Use of antioxidant vitamin supplements
Number of subjects: 94
Study 10196018 — intervention group
Group type: COMPARATOR
Intervention: High intake of protein, fat, monounsaturated fatty acids, and all/n-3 polyunsaturated fatty acids
Number of subjects: 94
Study 10196018 — intervention group
Group type: COMPARATOR
Intervention: Episodes of tonsillitis
Number of subjects: 94
Study 10196018 — intervention group
Group type: COMPARATOR
Intervention: Exposure to organic solvents
Number of subjects: 94
Study 7757360 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulating agents (specific agents not detailed)
Number of subjects: 0
Study 7757360 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemiluminescent analysis
Number of subjects: 0
Study 2184637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (0.02 to 0.04 mg/kg)
Number of subjects: 38
Study 2184637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine (0.1 to 0.2 mg/kg)
Number of subjects: 38
Study 2184637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine and Vinblastine (combined)
Number of subjects: 38
Study 760738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg intravenous injection
Number of subjects: 4
Study 760738 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine pretreatment
Number of subjects: 4
Study 760738 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg oral dose
Number of subjects: 4
Study 760738 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine treatment (various doses)
Number of subjects: 4
Study 30039982 — intervention group
Group type: EXPERIMENTAL
Intervention: KH-204
Number of subjects: 78
Study 30039982 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study 30740933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 54
Study 30740933 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 54
Study 27873094 — intervention group
Group type: EXPERIMENTAL
Intervention: EBR (50 mg) + GZR (50 mg) for 12 weeks
Number of subjects: 336
Study 27873094 — intervention group
Group type: EXPERIMENTAL
Intervention: EBR (50 mg) + GZR (100 mg) for 12 weeks
Number of subjects: 336
Study 27873094 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with EBR (50 mg) + GZR (100 mg) for 12 weeks (noncirrhotic patients)
Number of subjects: 336
Study 27873094 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with EBR (50 mg) + GZR (100 mg) for 12 weeks (cirrhotic patients)
Number of subjects: 336
Study 27873094 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment with EBR (50 mg) + GZR (100 mg) for 12 weeks (noncirrhotic patients)
Number of subjects: 336
Study 25602456 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP (N = 20)
Number of subjects: 40
Study 25602456 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen mask management (Control group, N = 20)
Number of subjects: 40
Study 25191890 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia implants (test group)
Number of subjects: 19
Study 25191890 — intervention group
Group type: COMPARATOR
Intervention: Titanium implants (control group)
Number of subjects: 19
Study 22710004 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 22710004 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 19049326 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week
Number of subjects: 284
Study 19049326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 17333359 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Risers 'Skills for Success' intervention
Number of subjects: 151
Study 17333359 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study 15247111 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block
Number of subjects: 60
Study 15247111 — intervention group
Group type: COMPARATOR
Intervention: Combined femoral (3‐in‐1) and sciatic blocks
Number of subjects: 60
Study 11441529 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (C-test)
Number of subjects: 18
Study 11441529 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P-test)
Number of subjects: 18
Study 9710370 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential RCMS magnetic field exposures
Number of subjects: 0
Study 9710370 — intervention group
Group type: EXPERIMENTAL
Intervention: RCMS exposures during work
Number of subjects: 0
Study 9710370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined RCMS exposures at work and home
Number of subjects: 0
Study 9710370 — intervention group
Group type: COMPARATOR
Intervention: Magnetic field intensity, intermittence, or cumulative exposure
Number of subjects: 0
Study 7988012 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 0
Study 7988012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol
Number of subjects: 0
Study 7988012 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B (apoB)
Number of subjects: 0
Study 7988012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein(a) [Lp(a)]
Number of subjects: 0
Study 7988012 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL) cholesterol
Number of subjects: 0
Study 7988012 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoA-I
Number of subjects: 0
Study 7988012 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study 7988012 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormones
Number of subjects: 0
Study 7988012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 0
Study 7988012 — intervention group
Group type: EXPERIMENTAL
Intervention: Von Willebrand factor
Number of subjects: 0
Study 7988012 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-load plasma glucose and insulin concentrations
Number of subjects: 0
Study 2743469 — intervention group
Group type: EXPERIMENTAL
Intervention: Somophyllin-CRT
Number of subjects: 0
Study 2743469 — intervention group
Group type: EXPERIMENTAL
Intervention: TheoDur
Number of subjects: 0
Study 2743469 — intervention group
Group type: COMPARATOR
Intervention: Intravenous aminophylline infusion
Number of subjects: 0
Study 31058633 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary bacterial count among participants
Number of subjects: 60
Study 31058633 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor oral hygiene
Number of subjects: 60
Study 31058633 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis
Number of subjects: 60